title: IART (Intra-Operative Avidination for Radionuclide Therapy) for accelerated radiotherapy in breast cancer patients. Technical aspects and preliminary results of a phase II study with 90Y-labelled biotin.
abstract: BACKGROUND
  Breast conserving surgery (BCS) plus external beam radiotherapy (EBRT) is considered the standard treatment for early breast cancer. We have investigated the possibility of irradiating the residual gland, using an innovative nuclear medicine approach named IART(®) (Intra-operative Avidination for Radionuclide Therapy).
  
  
  OBJECTIVE
  The objective of this study was to determine the optimal dose of avidin with a fixed activity (3.7 GBq) of (90)Y-biotin, in order to provide a boost of 20 Gy, followed by EBRT to the whole breast (WB) at the reduced dose of 40 Gy. Local and systemic toxicity, patient's quality of life, including the cosmetic results after the combined treatment with IART(®) and EBRT, were assessed.
  
  
  METHODS
  After tumour excision, the surgeon injected native avidin diluted in 30 ml of saline solution into and around the tumour bed (see video). Patients received one of three avidin dose levels: 50 mg (10 pts), 100 mg (15 pts) and 150 mg (10 pts). Between 12 to 24 h after surgery, 3.7 GBq (90)Y-biotin spiked with 185 MBq (111)In-biotin was administered intravenously (i.v.). Whole body scans and SPECT images were performed up to 30 h post-injection for dosimetric purposes. WB-EBRT was administered four weeks after the IART(®) boost. Local toxicity and quality of life were evaluated.
  
  
  RESULTS
  Thirty-five patients were evaluated. No side effects were observed after avidin administration and (90)Y-biotin infusion. An avidin dose level of 100 mg resulted the most appropriate in order to deliver the required radiation dose (19.5 ± 4.0 Gy) to the surgical bed. At the end of IART(®), no local toxicity occurred and the overall cosmetic result was good. The tolerance to the reduced EBRT was also good. The highest grade of transient local toxicity was G3, which occurred in 3/32 pts following the completion of WB-EBRT. The combination of IART(®)+EBRT was well accepted by the patients, without any changes to their quality of life.
  
  
  CONCLUSIONS
  These preliminary results support the hypothesis that IART(®) may represent a valid approach to accelerated WB irradiation after BCS. We hope that this nuclear medicine technique will contribute to a better management of breast cancer patients.
authors.affiliation: Division of Nuclear Medicine.
authors.forename: G
authors.initials: G
authors.lastname: Paganelli
authors.forename: C
authors.initials: C
authors.lastname: De Cicco
authors.forename: M E
authors.initials: ME
authors.lastname: Ferrari
authors.forename: G
authors.initials: G
authors.lastname: McVie
authors.forename: G
authors.initials: G
authors.lastname: Pagani
authors.forename: M C
authors.initials: MC
authors.lastname: Leonardi
authors.forename: M
authors.initials: M
authors.lastname: Cremonesi
authors.forename: A
authors.initials: A
authors.lastname: Ferrari
authors.forename: M
authors.initials: M
authors.lastname: Pacifici
authors.forename: A
authors.initials: A
authors.lastname: Di Dia
authors.forename: F
authors.initials: F
authors.lastname: Botta
authors.forename: R
authors.initials: R
authors.lastname: De Santis
authors.forename: V
authors.initials: V
authors.lastname: Galimberti
authors.forename: A
authors.initials: A
authors.lastname: Luini
authors.forename: R
authors.initials: R
authors.lastname: Orecchia
authors.forename: U
authors.initials: U
authors.lastname: Veronesi